Prediction of coronary heart disease using risk factor categories.
暂无分享,去创建一个
D. Levy | R. D'Agostino | P. Wilson | W. Kannel | Daniel Levy | A. Bélanger | H. Silbershatz | W. Kannel | Peter W.F. Wilson | Ralph B. D'Agostino | Daniel Levy | Albert M. Belanger | Halit Silbershatz | Ralph B. D’Agostino | R. D’Agostino | P. Wilson
[1] B. Brodie,et al. A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity. , 1952, The Journal of biological chemistry.
[2] T E Walsh,et al. Reporting results. , 1969, Archives of otolaryngology.
[3] R. Levy,et al. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.
[4] W. Kannel,et al. Differences in coronary heart disease in Framingham, Honolulu and Puerto Rico. , 1974, Journal of chronic diseases.
[5] Michael H. Kutner. Applied Linear Statistical Models , 1974 .
[6] R. Brand,et al. Multivariate Prediction of Coronary Heart Disease in the Western Collaborative Group Study Compared to the Findings of the Framingham Study , 1976, Circulation.
[7] W. Haskell,et al. The distribution of plasma lipoproteins in middle-aged male runners. , 1976, Metabolism: clinical and experimental.
[8] Statistical design considerations in the NHLI multiple risk factor intervention trial (MRFIT). The Multiple Risk Factor Intervention Trial Group. , 1977, Journal of Chronic Diseases.
[9] W. Kannel,et al. Diabetes, blood lipids, and the role of obesity in coronary heart disease risk for women. The Framingham study. , 1977, Annals of internal medicine.
[10] W. Kannel,et al. An investigation of coronary heart disease in families. The Framingham offspring study. , 1979, American journal of epidemiology.
[11] D L McGee,et al. Diabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: The Framingham Study , 1979, Diabetes Care.
[12] W. Kannel,et al. Multiple risk functions for predicting coronary heart disease: the concept, accuracy, and application. , 1982, American heart journal.
[13] E. Barrett-Connor,et al. Estrogen use and all-cause mortality. Preliminary results from the Lipid Research Clinics Program Follow-Up Study. , 1983, JAMA.
[14] Pasley Bh,et al. Prescribing estrogen during menopause: physician survey of practices in 1974 and 1981. , 1984 .
[15] B. Pasley,et al. Prescribing estrogen during menopause: physician survey of practices in 1974 and 1981. , 1984, Public health reports (1974).
[16] P. Wilson,et al. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study. , 1985, The New England journal of medicine.
[17] C. Caspersen,et al. Physical activity and the incidence of coronary heart disease. , 1987, Annual review of public health.
[18] P. Wilson,et al. Coronary risk prediction in adults (the Framingham Heart Study) , 1987, The American journal of cardiology.
[19] W. Kannel,et al. Representativeness of the Framingham risk model for coronary heart disease mortality: a comparison with a national cohort study. , 1987, Journal of chronic diseases.
[20] K. Anderson,et al. Longitudinal and secular trends in lipoprotein cholesterol measurements in a general population sample. The Framingham Offspring Study. , 1987, Atherosclerosis.
[21] D H Blankenhorn,et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. , 1987, JAMA.
[22] R. D'Agostino,et al. Fibrinogen and risk of cardiovascular disease. The Framingham Study. , 1987, JAMA.
[23] P. Wilson,et al. Leisure time physical activity in the Framingham Offspring Study. Description, seasonal variation, and risk factor correlates. , 1989, American journal of epidemiology.
[24] D. Reed,et al. Is elevated serum cholesterol level a risk factor for coronary heart disease in the elderly? , 1990, JAMA.
[25] W. Raub. From the National Institutes of Health. , 1990, JAMA.
[26] W. Kannel,et al. Parental history is an independent risk factor for coronary artery disease: the Framingham Study. , 1990, American heart journal.
[27] P. Wilson,et al. High-density lipoprotein, low-density lipoprotein and coronary artery disease. , 1990, The American journal of cardiology.
[28] G A Colditz,et al. A meta-analysis of physical activity in the prevention of coronary heart disease. , 1990, American journal of epidemiology.
[29] R. D'Agostino,et al. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. , 1990, American heart journal.
[30] P. Wilson,et al. Calculated values for low-density lipoprotein cholesterol in the assessment of lipid abnormalities and coronary disease risk. , 1990, Clinical chemistry.
[31] R. Paffenbarger,et al. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. , 1991, The New England journal of medicine.
[32] K. Anderson,et al. An updated coronary risk profile. A statement for health professionals. , 1991, Circulation.
[33] G A Colditz,et al. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. , 2004, Preventive medicine.
[34] Estrogen and coronary heart disease in women. , 1991 .
[35] K. Anderson,et al. Cardiovascular disease risk profiles. , 1991, American heart journal.
[36] E. Barrett-Connor,et al. Estrogen and coronary heart disease in women , 1991, JAMA.
[37] J. Manson,et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. , 1991, The New England journal of medicine.
[38] National Education Programs Working Group report on the management of patients with hypertension and high blood cholesterol. , 1991, Annals of Internal Medicine.
[39] Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. , 1991 .
[40] G. Colditz,et al. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence☆☆☆ , 1991 .
[41] G. Myers,et al. Blood lipid measurements: Variations and practical utility , 1992, Journal of the American Medical Association (JAMA).
[42] M. Abrahamowicz,et al. The benefits of treating hyperlipidemia to prevent coronary heart disease. Estimating changes in life expectancy and morbidity. , 1992, JAMA.
[43] Blood lipid measurements: Variations and practical utility , 1992, JAMA.
[44] The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V) , 1993, Archives of internal medicine.
[45] E. Ernst,et al. Fibrinogen as a Cardiovascular Risk Factor , 1993, Annals of Internal Medicine.
[46] W. Kannel,et al. Hypercholesterolemia and Coronary Risk in the Elderly: The Framingham Study. , 1993, The American journal of geriatric cardiology.
[47] Donald A. Smith. Fibrinogen as a cardiovascular risk factor: a meta-analysis , 1993, ACP Journal Club.
[48] F. Kummerow,et al. Viewpoint on the Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. , 1993, Journal of the American College of Nutrition.
[49] J. Mckenney,et al. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) , 1993, JAMA.
[50] Bruce Kinosian,et al. Cholesterol and Coronary Heart Disease: Predicting Risks by Levels and Ratios , 1994, Annals of Internal Medicine.
[51] P. Wood. Physical activity, diet, and health: independent and interactive effects. , 1994, Medicine & Science in Sports & Exercise.
[52] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.
[53] Diana B. Petitti,et al. Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine , 1994 .
[54] L. Wilkins. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). , 1994 .
[55] L. Wilkins,et al. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). , 1994, Circulation.
[56] J. Stengård,et al. Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.
[57] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .
[58] K. Yano,et al. Distribution and correlates of insulin in elderly men. The Honolulu Heart Program. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[59] R S Paffenbarger,et al. Exercise intensity and longevity in men. The Harvard Alumni Health Study. , 1995, JAMA.
[60] F. Galetta,et al. [Fibrinogen as a cardiovascular risk factor]. , 1995, Minerva cardioangiologica.
[61] D. Levy. Have expert panel guidelines kept pace with new concepts in hypertension? , 1995, The Lancet.
[62] L. Coupal,et al. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? , 1995, JAMA.
[63] Cholesterol screening. Once is not enough. , 1995, Archives of internal medicine.
[64] R. Glynn,et al. HDL cholesterol predicts coronary heart disease mortality in older persons. , 1995, JAMA.
[65] U. Goldbourt,et al. Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study. , 1995, Journal of clinical epidemiology.
[66] C. A. Ferguson,et al. Immunoseparation method for measuring low-density lipoprotein cholesterol directly from serum evaluated. , 1995, Clinical chemistry.
[67] T. Lancet,et al. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials , 1996, The Lancet.
[68] P. Macfarlane,et al. West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials , 1996 .
[69] F. Harrell,et al. Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .
[70] A. Folsom,et al. Recent trends in acute coronary heart disease--mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators. , 1996, The New England journal of medicine.
[71] L. Ramsay,et al. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table , 1996, The Lancet.
[72] Ames,et al. PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .
[73] D.,et al. Regression Models and Life-Tables , 2022 .